Suppr超能文献

奥氮平与丙戊酸镁和拉莫三嗪在抗 N-甲基-D-天冬氨酸受体脑炎中的比较:一项回顾性研究。

Olanzapine vs. magnesium valproate vs. lamotrigine in anti-N-methyl-D-aspartic acid receptor encephalitis: a retrospective study.

机构信息

College of Clinical Medicine, Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China.

Department of Neurology, Brain Hospital of Hunan Province (The Second Hospital of Hunan Province), Changsha, 410007, Hunan, China.

出版信息

BMC Neurol. 2024 Sep 9;24(1):331. doi: 10.1186/s12883-024-03811-z.

Abstract

BACKGROUND

This study aimed to compare the impact of olanzapine, magnesium valproate, and lamotrigine as adjunctive treatments for anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. And it is expected to add supporting points related to the rebalance of neurotransmitters in the brain through adjuvant therapy in the clinical management of anti-NMDAR encephalitis.

METHODS

This retrospective study included patients diagnosed with anti-NMDAR encephalitis who received standardized immunotherapy at Hunan Brain Hospital between January 2018 and December 2020.

RESULTS

Compared to the olanzapine group, both the magnesium valproate and lamotrigine groups showed lower scores on the positive and negative symptom scale (PANSS) total score after 3 weeks of treatment (all P < 0.05). The Montreal Cognitive Assessment Scale (MoCA) scores in the magnesium valproate and lamotrigine groups were significantly higher than in the olanzapine group after 3 weeks and 3 months of treatment (all P < 0.05). After 3 months of treatment, the proportions of patients with a modified Rankin scale score (mRS) of 0-1 in the magnesium valproate and lamotrigine groups were significantly higher than in the olanzapine group (all P < 0.05). The electroencephalogram (EEG) abnormality ranks at 3 months were significantly lower in the magnesium valproate and lamotrigine groups compared with the olanzapine group (all P < 0.05). Furthermore, the Glx/Cr ratio significantly decreased after 3 months of treatment (all P < 0.05) in the magnesium valproate and lamotrigine groups, while the Glx/Cr ratio in the olanzapine group showed no significant change (P > 0.05).

CONCLUSION

Compared with olanzapine, the addition of magnesium valproate or lamotrigine to immunotherapy might be associated with a lower PANSS score, higher MoCA score, and lower mRS score. The improvement of neurological functions and cognitive function may be related to the decreased Glx/Cr ratio.

摘要

背景

本研究旨在比较奥氮平、丙戊酸镁和拉莫三嗪作为抗 N-甲基-D-天冬氨酸受体(NMDAR)脑炎的辅助治疗的影响,并期望通过辅助治疗在抗 NMDAR 脑炎的临床管理中添加与大脑神经递质再平衡相关的要点。

方法

这项回顾性研究纳入了 2018 年 1 月至 2020 年 12 月在湖南省脑科医院接受标准化免疫治疗的抗 NMDAR 脑炎患者。

结果

与奥氮平组相比,丙戊酸镁组和拉莫三嗪组在治疗 3 周后阳性和阴性症状量表(PANSS)总分均降低(均 P < 0.05)。丙戊酸镁组和拉莫三嗪组在治疗 3 周和 3 个月后蒙特利尔认知评估量表(MoCA)评分明显高于奥氮平组(均 P < 0.05)。治疗 3 个月后,丙戊酸镁组和拉莫三嗪组的改良 Rankin 量表评分(mRS)为 0-1 的患者比例明显高于奥氮平组(均 P < 0.05)。与奥氮平组相比,丙戊酸镁组和拉莫三嗪组的脑电图(EEG)异常等级在 3 个月时明显降低(均 P < 0.05)。此外,丙戊酸镁组和拉莫三嗪组在治疗 3 个月后 Glx/Cr 比值显著降低(均 P < 0.05),而奥氮平组 Glx/Cr 比值无明显变化(P > 0.05)。

结论

与奥氮平相比,免疫治疗中添加丙戊酸镁或拉莫三嗪可能与较低的 PANSS 评分、较高的 MoCA 评分和较低的 mRS 评分相关。神经功能和认知功能的改善可能与 Glx/Cr 比值降低有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/951c/11382376/c1639b75aa6a/12883_2024_3811_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验